EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Metformin, Maternal Glycemic Control, and Neonatal Hypoglycemia After Antenatal Steroids

Enav Yefet, Manal Massalha, Gil Talmon, Aminet Labay, Marian Matanis, Erez Sleman, Rima Nassra, Maya Frank Wolf, Inshirah Sgayer, Lior Lowenstein, Zohar Nachum

JAMA Network Open · 2026

DOI: 10.1001/jamanetworkopen.2025.52807 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2026. Verfasst von Enav Yefet und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Tzafon Medical Center, Poriya, Israel. Hauptthemen laut MEDLINE: Metformin, Hypoglycemia, Betamethasone, Hypoglycemic Agents. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Although betamethasone reduces complications of prematurity, it can cause maternal hyperglycemia and neonatal hypoglycemia. Metformin effectively treats maternal hyperglycemia and has been shown to decrease neonatal hypoglycemia in women with gestational diabetes.

Objective

To evaluate the impact of metformin treatment after betamethasone administration on maternal glycemic control and the incidence of neonatal hypoglycemia in preterm infants. Design, Setting, and Participants This multicenter, open-label randomized clinical trial was conducted from July 1, 2020, to June 30, 2024, at 3 medical centers in Israel. Pregnant women receiving betamethasone from 24.0 to 36.5 gestational weeks due to increased preterm delivery risk were studied. Women with diabetes were excluded.

Interventions

Participants were randomized to metformin (425 mg 3 times daily before meals and 850-1700 mg at 10 pm ) or no treatment. The treatment lasted up to 48 hours after the first betamethasone dose. Capillary glucose was measured before meals (preprandial), 90 minutes after starting meals (postprandial), and at 10 pm . Main Outcome and Measure The primary end points were the mean maternal glucose values up to 48 hours from first betamethasone injection and the rate of neonatal hypoglycemia in preterm deliveries (<37 gestational weeks).

Results

A total of 169 women (mean [SD] age, 29.7 [5.4] years), including 84 with 48 preterm infants in the metformin group and 85 with 58 preterm neonates in the control group, were included in the study. Mean (SD) maternal total and postprandial glucose values were significantly lower in the metformin group (121 [15] vs 127 [17] mg/dL; P = .01; and 129 [22] vs 138 [26] mg/dL; P = .009, respectively). Neonatal hypoglycemia rate was lower in the metformin group (10 [21%] vs 23 [40%]; P = .04; relative risk, 0.53; 95% CI, 0.28-0.99). Mild adverse effects, mostly gastrointestinal, were reported by 12 women (14%). Conclusions and Relevance In this randomized clinical trial, metformin was safe and effective in preventing betamethasone-induced maternal hyperglycemia and neonatal hypoglycemia. Metformin should be considered as a treatment option for women who receive antenatal corticosteroids to prevent their related adverse effects. Trial Registration ClinicalTrials.gov Identifier: NCT04332393

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminHypoglycemiaBetamethasoneHypoglycemic AgentsGlycemic ControlHyperglycemiaHumansFemalePregnancyInfant, NewbornAdultBlood GlucoseIsraelDiabetes, GestationalInfant, PrematureGlucocorticoidsInfant, Newborn, Diseases

Substanzen

MetforminBetamethasoneHypoglycemic AgentsBlood GlucoseGlucocorticoids

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Tzafon Medical Center, Poriya, Israel.
  • Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
  • Department of Obstetrics and Gynecology, Emek Medical Center, Afula, Israel.
  • The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
  • Neonatology Department, Emek Medical Center, Afula, Israel.
  • Raya Strauss Wing of Obstetrics and Gynecology, Galilee Medical Center, Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.

Zitieren

APA

Yefet, E., Massalha, M., Talmon, G., Labay, A., Matanis, M., Sleman, E., Nassra, R., Frank Wolf, M., Sgayer, I., Lowenstein, L., & Nachum, Z. (2026). Metformin, Maternal Glycemic Control, and Neonatal Hypoglycemia After Antenatal Steroids. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.52807

Vancouver

Yefet E, Massalha M, Talmon G, Labay A, Matanis M, Sleman E, et al. Metformin, Maternal Glycemic Control, and Neonatal Hypoglycemia After Antenatal Steroids. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2025.52807

BibTeX
@article{Yefet2026,
  author = {Yefet, Enav and Massalha, Manal and Talmon, Gil and Labay, Aminet and Matanis, Marian and Sleman, Erez and Nassra, Rima and Frank Wolf, Maya and Sgayer, Inshirah and Lowenstein, Lior and Nachum, Zohar},
  title = {Metformin, Maternal Glycemic Control, and Neonatal Hypoglycemia After Antenatal Steroids},
  journal = {JAMA Network Open},
  year = {2026},
  doi = {10.1001/jamanetworkopen.2025.52807}
}
Kostenlos starten →